西妥昔单抗联合伊立替康治疗转移性结直肠癌的临床观察
[摘要] 目的 观察转移性结直肠癌应用西妥昔单抗联合伊立替康治疗的临床效果。 方法 选择2012年2月～2017年7月本院收治的经组织学或细胞学证实确诊的转移性结直肠癌患者106例作为观察对象。其中54例患者作为观察组，52例患者作为对照组，分别采取西妥昔单抗联合伊立替康治疗及伊利替康（一般采用FOLFIRI方案）治疗方法进行临床观察。比较两组临床效果。 结果 观察组治疗后总有效率及控制率均高于对照组，差异有统计学意义（P<0.05）;两组均有毒副反应，且组间毒副反应率比较差异无统计学意义（P>0.05）。 结论 应用西妥昔单抗联合伊立替康化疗方案治疗转移性结直肠癌患者效果较好。
[关键词] 西妥昔单抗;转移性结直肠癌;免疫治疗;伊立替康
[中图分类号] R735.3 [文献标识码] A [文章编号] 1673-9701（2019）04-0028-03
[Abstract] Objective To observe the clinical effect of cetuximab combined with irinotecan in the treatment of metastatic colorectal cancer. Methods A total of 106 patients with metastatic colorectal cancer confirmed by histology or cytology treated in our hospital from February 2012 to July 2017 were selected， and 54 patients were used as observation group and 52 patients were used as control group. Cetuximab combined with irinotecan and irinotecan only（usually FOLFIRI regimen）were used respectively for the two groups. The clinical effect of the two groups was compared. Results The total effective rate and control rate of the observation group were higher than those of the control group， and the differences were statistically significant（P<0.05）. Toxic side effects were observed in the two groups， whose incidence rates showed no statistically significant difference（P>0.05）. Conclusion The efficacy of cetuximab combined with irinotecan chemotherapy is better in the treatment of patients with metastatic colorectal cancer.
[Key words] Cetuximab;Metastatic colorectal cancer;Immunoth...
|
== 试读已结束，如需继续阅读敬请充值会员 ==
|
|
本站文章均为原创投稿，仅供下载参考，付费用户可查看完整且有格式内容！
(费用标准：38元/2月，98元/2年，微信支付秒开通！) |
| 升级为会员即可查阅全文 。如需要查阅全文，请 免费注册 或 登录会员 |
|
